期刊
NATURE PROTOCOLS
卷 8, 期 11, 页码 2079-2089出版社
NATURE PUBLISHING GROUP
DOI: 10.1038/nprot.2013.121
关键词
-
资金
- European Molecular Biology Organization (EMBO)
- Novartis Foundation
- ETH Zurich
- Swiss National Science Foundation
- SwissBridge/Stammbach Stiftung
- Kommission fur Technologie und Innovation (KTI)
- Philochem AG
- Philogen SpA
A ntibody-drug conjugates (ADCs) are promising agents for the selective delivery of cytotoxic drugs to specific cells (for example, tumors). In this protocol, we describe two strategies for the precise modification at engineered C-or N-terminal cysteines of antibodies in IgG, diabody and small immunoprotein (SIP) formats that yield homogenous ADCs. In this protocol, cemadotin derivatives are used as model drugs, as these agents have a potent cytotoxic activity and are easy to synthesize. However, other drugs with similar functional groups could be considered. In the first approach, a cemadotin derivative containing a sulfhydryl group results in a mixed disulfide linkage. In the second approach, a cemadotin derivative containing an aldehyde group is joined via a thiazolidine linkage. The procedures outlined are robust, enabling the preparation of ADCs with a defined number of drugs per antibody in a time frame between 7 and 24 h.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据